Advanced Kidney cancer can be kept under control for long periods with current treatments.

Combination of immunotherapy and agents targeting VEGF are commonly used in 1st line treatment of advanced Kidney cancers.

For those patients who cancers stop responding to these above treatments, there is good news.

A new agent targeting cancers in a different way has become available recently and updated results are very encouraging.

This new drug called Belzutifan targets a different weak spot in the cancer. Belzutifan has shown better cancer control rates when compared to another drug called Everolimus.

Belzutifan results are being presented at ESMO congress in Barcelona

Belzutifan will become a standard of care in this setting now

Reference

ESMO news. Belzutifan Shows a Significant Benefit Over Everolimus in Patients with Advanced Clear Cell RCC After Both ICI and Antiangiogenic Therapies

NEJM Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.